Drug Trial Radar · NCT07832136
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Apr 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Viridian Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but subsequently had a disease recurrence.
Conditions
- Thyroid Eye Disease
Interventions
veligrotrug (LUMVOA™)Drug
intravenous infusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of veligrotrug (LUMVOA™)Time frame: Through Week 15
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Office of Dr. Amy Patel Jain, MD
Newport Beach, California
Sarasota Retina Institute
Sarasota, Florida
Ophthalmic Consultants of Boston
East Weymouth, Massachusetts
Kahana Oculoplastic & Orbital Surgery
Livonia, Michigan
University Health
Kansas City, Missouri
The Center for Eye and Facial Plastic Surgery
Somerset, New Jersey
Neuro-Eye Clinical Trials
Houston, Texas
Baylor College of Medicine Alkek Eye Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.